Citations

Clear

6274 citation(s) found for "To, Andrew".

Ultrasonic Aspiration for Debulking Infiltrative Masses of the Orbit
Sun, Susan , Stewart, Krista J., Lyford-Pike, Sofía , Garrity, James A., Harrison, Andrew R. , Mokhtarzadeh, Ali , Stewart, Krista

Mayo Clinic

Ophthalmic Plastic & Reconstructive Surgery | December 23, 2019 | Volume: 36 | Issue: 2 | Pages: 198-201

10.1097/iop.0000000000001537 | PMID 31868794 Get It

Purpose: To demonstrate the utility of an ultrasonic aspirator (Sonopet, Stryker Corporation; Kalamazoo, MI) for debulking firm, soft tissue masses of the orbit. Methods: Case series. The ultrasonic aspirator was used to debulk firm, soft tissue masses in 3 cases. The initial patient had a large orbitofacial mass extending to the inferior and lateral orbital apex secondary to IgG4 disease. The second patient had a lacrimal sac adenocarcinoma extending to the medial orbital apex. The third patient had a large orbital mass extending to the apex secondary to granulomatosis with polyangiitis. Results: The ultrasonic aspirator facilitated debulking of infiltrative firm soft tissue masses of the orbit. The device’s ability to emulsify, irrigate, and aspirate, along with its small footprint, facilitated precise sculpting and debulking to an extent which would have been difficult otherwise due to location. Conclusions: The ultrasonic aspirator allows precise sculpting of infiltrative firm soft tissue masses in the orbit and is particularly useful in cases with challenging anatomical access.
Hypoglycemia and Glycemic Control in Older Adults With Type 1 Diabetes: Baseline Results From the WISDM Study
Carlson, Anders L. , Miller, Kellee M. , Ahmann, Andrew , Chaytor, Naomi , Fox, Steven V., Kiblinger, Lisa, Kruger, Davida , Salam, Maamoun , Young, Laura , Kudva, Yogish C. , Group, for the WISDM Study, Miller, Kellee M , Salam, Maamoun , Kanapka, Lauren , Fox, Steven, Levy, Carol J. , Peters, Anne L. , Rickels, Michael R. , Shah, Viral N. , Pratley, Richard E. , Group, for the WISDM Study

Mayo Clinic

Journal of Diabetes Science and Technology | December 21, 2019 | Volume: 15 | Issue: 3 | Pages: 582-592

10.1177/1932296819894974 | PMID 31867988 Get It

Background: Knowledge regarding the burden and predictors of hypoglycemia among older adults with type 1 diabetes (T1D) is limited. Methods: We analyzed baseline data from the Wireless Innovations for Seniors with Diabetes Mellitus (WISDM) study, which enrolled participants at 22 sites in the United States. Eligibility included clinical diagnosis of T1D, age ≥60 years, no real-time continuous glucose monitoring (CGM) use in prior three months, and HbA1c <10.0%. Blinded CGM data from 203 participants with at least 240 hours were included in the analyses. Results: Median age of the cohort was 68 years (52% female, 93% non-Hispanic white, and 53% used insulin pumps). Mean HbA1c was 7.5%. Median time spent in the glucose range <70 mg/dL was 5.0% (72 min/day) and <54 mg/dL was 1.6% (24 min/day). Among all factors analyzed, only reduced hypoglycemia awareness was associated with greater time spent <54 mg/dL (median time of 2.7% vs 1.3% [39 vs 19 minutes per day] for reduced awareness vs aware/uncertain, respectively, P = .03). Participants spent a mean 56% of total time in target glucose range of 70-180 mg/dL and 37% of time above 180 mg/dL. Conclusions: Over half of older T1D participants spent at least an hour a day with glucose levels <70 mg/dL. Those with reduced hypoglycemia awareness spent over twice as much time than those without in a serious hypoglycemia range (glucose levels <54 mg/dL). Interventions to reduce exposure to clinically significant hypoglycemia and increase time in range are urgently needed in this age group.
Symptom checkers versus doctors: A prospective, head‐to‐head comparison for cough
Berry, Andrew C. , Berry, Nicholas A. , Wang, Bin , Mulekar, Madhuri S. , Melvin, Anne, Battiola, Richard J., Bulacan, Frederick K., Berry, Bruce B.

Mayo Clinic

The Clinical Respiratory Journal | December 20, 2019 | Volume: 14 | Issue: 4 | Pages: 413-415

10.1111/crj.13135 | PMID 31860762 Get It

Endoscopic Ultrasound/Fine Needle Aspiration Is Effective for Lymph Node Staging in Patients With Cholangiocarcinoma
Malikowski, Thomas, Levy, Michael J. , Gleeson, Ferga C. , Topazian, Mark , Iyer, Prasad G. , Rajan, Elizabeth , Roberts, Lewis R. , Abu Dayyeh, Barham K, Roberts, Lewis R , Levy, Michael J. , Storm, Andrew C. , Vargas, Eric J. , Dayyeh, Barham K. Abu , Gores, Gregory J. , Chandrasekhara, Vinay

Mayo Clinic

Hepatology | December 20, 2019 | Volume: 72 | Issue: 3 | Pages: 940-948

10.1002/hep.31077 | PMID 31860935 Get It

Background and Aims Presence of malignant regional lymph nodes (MRLNs) precludes curative oncological resection or liver transplantation for cholangiocarcinoma (CCA). Limited data support the utility of endoscopic ultrasound (EUS)/fine needle aspiration (FNA) for detection of MRLNs in extrahepatic CCA, but there are no data for its role in intrahepatic CCA (iCCA). The aim of this study is to evaluate the staging impact of EUS for CCA, including analysis by subtype. Approach and Results We identified consecutive patients with CCA who underwent EUS staging at a single tertiary care center from October 2014 to April 2018. Among this cohort, we abstracted clinical demographic, radiographical, procedural, cytopathological, and surgical data. STATA 15 software was used for comparative analysis calculations (StataCorp LP, College Station, TX). The study cohort included 157 patients; 24 (15%), 124 (79%), and 9 (6%) with intrahepatic, perihilar, and distal CCA, respectively. EUS was able to identify regional lymph nodes (RLNs) in a higher percentage of patients compared to cross‐sectional imaging (86% vs. 47%; P < 0.001). FNA was performed in 133 (98.5%) patients with RLNs, with a median of three passes per node. EUS‐FNA identified MRLN in 27 of 31 (87.1%) patients ultimately found to have MRLNs. For iCCA, EUS detected a higher percentage of RLN compared to cross‐sectional imaging (83% vs. 50%; P = 0.048), with MRLNs identified in 4 (17%) patients. Among the entire cohort, identification of at least one MRLN by EUS was associated with lower median survival (353 vs. 1,050 days; P < 0.001) and increased risk of death (hazard ratio = 4.1; P < 0.001). Conclusions EUS‐FNA is effective for identifying MRLN in patients with CCA, and should be routinely incorporated into staging of all CCA subtypes given the impact of MRLN on prognosis and management decisions.
Epidemiology of injuries from fire, heat and hot substances: global, regional and national morbidity and mortality estimates from the Global Burden of Disease 2017 study
James, Spencer L , Lucchesi, Lydia R , Bisignano, Catherine, Castle, Chris D, Dingels, Zachary V, Fox, Jack T, Hamilton, Erin B, Henry, Nathaniel J , McCracken, Darrah, Sylte, Dillon O , Ahmadi, Alireza , Alahdab, Fares , Alipour, Vahid , Andualem, Zewudu , Arabloo, Jalal , Badiye, Ashish , Bagherzadeh, Mojtaba , Banstola, Amrit , Bärnighausen, Till , Barzegar, Akbar , Bayati, Mohsen , Bhaumik, Soumyadeep , Bijani, Ali , Bukhman, Gene , Carvalho, Félix , Crowe, Christopher S. , Dalal, Koustuv , Nasab, Mostafa Dianati, Endries, Aman Yesuf , Fernandes, Eduarda , Fischer, Florian , Fukumoto, Takeshi, Gebremedhin, Ketema Bizuwork , Gebremeskel, Gebreamlak Gebremedhn , Gilani, Syed Amir , Haagsma, Juanita A., Hostiuc, Sorin , Househ, Mowafa , Igumbor, Ehimario , Irvani, Seyed Sina Naghibi , Kahsay, Amaha , Kapoor, Neeti , Kasaeian, Amir , Khader, Yousef , Khalil, Ibrahim A, Khan, Ejaz Ahmad , Khazaee-Pool, Maryam , Kokubo, Yoshihiro , Madadin, Mohammed , Majdán, Marek , Maled, Venkatesh , Manafi, Navid , Manafi, Ali, Mangalam, Srikanth , Massenburg, Benjamin B. , Meles, Hagazi Gebre , Menezes, Ritesh G. , Meretoja, Tuomo J , Miazgowski, Bartosz , Miller, Ted R. , Mohammadian-Hafshejani, Abdollah , Negoi, Ionuţ , Nguyen, Son Hoang , Nguyen, Cuong Tat , Nixon, Molly R, Olagunju, Andrew T , Olagunju, Tinuke O , Padubidri, Jagadish Rao , Polinder, Suzanne , Rabiee, Navid , Rahimi‐Movaghar, Vafa , Rawaf, David Laith , Rezapour, Aziz , Rickard, Jennifer , Roro, Elias Merdassa , Roy, Nobhojit , Salamati, Payman, Samy, Abdallah M , Satpathy, Maheswar , Sawhney, Monika, Schwebel, David C. , Senthilkumaran, Subramanian , Shigematsu, Mika, Tohidinik, Hamid Reza , Valdéz, Pascual , Wijeratne, Tissa , Yisma, Engida , Zaidi, Zoubida , Zhang, Zhi-Jiang, Hay, Simon I , Mokdad, Ali H. , Dianatinasab, Mostafa , Wijeratne, T , Roberts, Nicholas L S , Ahmed, Muktar Beshir , Antonio, Carl Abelardo T. , Daryani, Ahmad , Do, Hoa , Do, Huyen Phuc , Filip, Irina , Fukumoto, Takeshi, Hamidi, Samer , Ilesanmi, Olayinka Stephen , Jayatilleke, Achala Upendra , Khalil, Ibrahim A, Lopez, Alan D , Malekzadeh, Reza , Mohammadpourhodki, Reza , Morrison, Shane D. , Nguyen, Trang Huyen , Rabiee, Mohammad , Radfar, Amir , Rawaf, Salman , Safari‐Faramani, Roya , Salamati, Payman, Sepanlou, Sadaf Ghajarieh , Soheili, Amin , Stokes, Mark Andrew , Tran, Bach Xuan , Zamani, Mohammad , Zhang, Zhi‐Jiang , Olagunju, Andrew T , Alahdab, Fares

Mayo Clinic

Injury Prevention | December 19, 2019 | Volume: 26 | Issue: Suppl 2 | Pages: i36-i45

10.1136/injuryprev-2019-043299 | PMID 31857422 Get It

Background Past research has shown how fires, heat and hot substances are important causes of health loss globally. Detailed estimates of the morbidity and mortality from these injuries could help drive preventative measures and improved access to care. Methods We used the Global Burden of Disease 2017 framework to produce three main results. First, we produced results on incidence, prevalence, years lived with disability, deaths, years of life lost and disability-adjusted life years from 1990 to 2017 for 195 countries and territories. Second, we analysed these results to measure mortality-to-incidence ratios by location. Third, we reported the measures above in terms of the cause of fire, heat and hot substances and the types of bodily injuries that result. Results Globally, there were 8 991 468 (7 481 218 to 10 740 897) new fire, heat and hot substance injuries in 2017 with 120 632 (101 630 to 129 383) deaths. At the global level, the age-standardised mortality caused by fire, heat and hot substances significantly declined from 1990 to 2017, but regionally there was variability in age-standardised incidence with some regions experiencing an increase (eg, Southern Latin America) and others experiencing a significant decrease (eg, High-income North America). Conclusions The incidence and mortality of injuries that result from fire, heat and hot substances affect every region of the world but are most concentrated in middle and lower income areas. More resources should be invested in measuring these injuries as well as in improving infrastructure, advancing safety measures and ensuring access to care.
390: POSTOPERATIVE HYPOTENSION IN THE CRITICALLY ILL IS ASSOCIATED WITH ADVERSE CLINICAL OUTCOMES
Stapelfeldt, Wolf H. , Boero, Isabel, Chen, Qinyu , Stevens, Mitali, Khanna, Ashish , Smischney, Nathan J. , Shaw, Andrew , Khanna, Ashish

Mayo Clinic

Critical Care Medicine | December 18, 2019 | Volume: 48 | Issue: 1 | Pages: 177-177

10.1097/01.ccm.0000619912.57919.d1 Get It

Ewing Sarcoma in Older Adults: A Clinicopathologic Study of 50 Cases Occurring in Patients Aged ≥40 Years, With Emphasis on Histologic Mimics
Jahanseir, Khadijeh, Folpe, Andrew L. , Graham, Rondell P. , Sukov, William R. , Fritchie, Karen , Sukov, William, Fritchie, Karen J , Graham, Rondell P , Giannini, Caterina , Robinson, Steven I.

Mayo Clinic

International Journal of Surgical Pathology | December 18, 2019 | Volume: 28 | Issue: 4 | Pages: 352-360

10.1177/1066896919893073 | PMID 31847636 Get It

Objective. We explore the clinicopathologic features of Ewing sarcoma (ES) presenting in older adulthood. Methods. Cases of molecularly confirmed ES arising in patients aged ≥40 years were evaluated. Results. Fifty patients were identified (33 males/17 females; 41-86 years). The majority of tumors (41) arose at extraskeletal sites, while 9 were bone primaries. Twenty-eight cases showed nested architecture, while the remaining cases showed sheet-like growth. Tumor cytology was categorized as conventional (n = 39), crushed (n = 5), clear cell (n = 4), rhabdoid (n = 3), and epithelioid (n = 2). Fifty percent had necrosis, while rosettes were noted in 1 case. Immunostains performed ranged from 1 to 28 (median = 10). Follow-up (n = 43, 1-147 months) revealed 15 patients with metastasis. Conclusion. Although rare, ES should be considered in the differential diagnosis for round cell malignancies in older adult patients. In this cohort, ES is most often extraskeletal, and may show unusual morphologic features, closely simulating more common neoplasms in this age group.
Cancer Risks Associated With GermlinePALB2Pathogenic Variants: An International Study of 524 Families
Yang, Xin , Doroszuk, Alicja, Schneider, Sandra , Allen, Jamie , Decker, Brennan , Redman, James , Scarth, James A. , Plaskocinska, Inga, Luccarini, Craig , Shah, Mitul , Pooley, Karen A. , Dorling, Leila , Lee, Andrew , Adank, Muriel A. , Aittomäki, Kristiina, Andrulis, Irene L. , Ang, Peter , Bernstein, Jonine L. , Bobolis, Kristie, Borg, Åke , Blomqvist, Carl , Claes, Kathleen , Cuggia, Adeline , Culver, Julie O. , Damiola, Francesca , Pauw, Antoine De , Dolinsky, Jill S. , Engel, Christoph , Evans, D. Gareth , Goode, Ellen L. , Gruber, Stephen B., Hahnen, Eric , Hake, Christopher R., Heikkinen, Tuomas , Hurley, Judith , Janavičius, Ramūnas , Kleibl, Zdeněk , Kleiblová, Petra , Konstantopoulou, Irene , Kvist, Anders , LaDuca, Holly , Lee, Ann S. G. , Lesueur, Fabienne , Mannermaa, Arto, Manoukian, Siranoush , McFarland, Rachel, McKinnon, Wendy, Meindl, Alfons , Metcalfe, Kelly , Taib, Nur Aishah Mohd , Moilanen, Jukka S. , Nathanson, Katherine L. , Ng, Pei Sze , Nguyen‐Dumont, Tú , Nielsen, Sarah M. , Obermair, Florian , Offit, Kenneth, Olopade, Olufunmilayo I. , Ottini, Laura , Penkert, Judith , Pylkäs, Katri , Ramus, Susan J. , Rudaitis, Vilius , Side, Lucy, Silva‐Smith, Rachel , Silvestri, Valentina , Skytte, Anne‐Bine , Slavin, Thomas, Soukupová, Jana , Trainer, Alison H., Unzeitig, Gary, Usha, Lydia , Hansen, Thomas van Overeem , Whitworth, James , Wood, Marie , Yip, Cheng Har , Yoon, Sook‐Yee , Yussuf, Amal , Zogopoulos, George , Goldgar, David E. , Chenevix‐Trench, Georgia , George, Sophia , Houdayer, Claude , James, Paul A. , El-Haffaf, Zaki, Ehrencrona, Hans , Janatová, Markéta , Peterlongo, Paolo , Nevanlinna, Heli, Schmutzler, Rita K., Teo, Soo‐Hwang , Weitzel, Jeffrey N. , Elliott, Aaron , Winqvist, Robert , Easton, Douglas F. , Antoniou, Antonis C. , Houdayer, Claude , James, Paul , Lesueur, Fabienne , Peterlongo, Paolo , Ramus, Susan J , Teo, Soo H , Weitzel, Jeffrey N , Claes, Kathleen B M , Ehrencrona, Hans , Evans, D Gareth , Konstantopoulou, Irene , Olopade, Olufunmilayo I , Silvestri, Valentina , Nathanson, Katherine L , Engel, Christoph , Nguyen-Dumont, Tu , Chenevix-Trench, Georgia , Ottini, Laura , Metcalfe, Kelly A , Pylkäs, Katri , Janatova, Marketa , Soukupova, Jana , Hansen, Thomas van Overeem , Kleibl, Zdenek , Manoukian, Siranoush , Mohd Taib, Nur Aishah , Decker, Brennan , Leslie, Goska , Dunning, Alison M. , Adlard, Julian , Barwell, Julian , CONCANNON, PATRICK J. , Dı́ez, Orland , Domchek, Susan M. , Fostira, Florentia , Garber, Judy E. , Golmard, Lisa , Maher, Eamonn R. , Mannermaa, Arto, Meindl, Alfons , Neuhausen, Susan L. , Radice, Paolo , Slavin, Thomas P. , Tondini, Carlo Alberto , Hopper, John L. , Pharoah, Paul D.P. , Balmañà, Judith , El-Haffaf, Zaki, Nevanlinna, Heli , Robson, Mark E. , Pal, Tuya , Couch, Fergus J. , Southey, Melissa C. , Foulkes, William D. , Tischkowitz, Marc D.

Mayo Clinic

Journal of Clinical Oncology | December 16, 2019 | Volume: 38 | Issue: 7 | Pages: 674-685

10.1200/jco.19.01907 | PMID 31841383 Get It

PURPOSETo estimate age-specific relative and absolute cancer risks of breast cancer and to estimate risks of ovarian, pancreatic, male breast, prostate, and colorectal cancers associated with germline PALB2 pathogenic variants (PVs) because these risks have not been extensively characterized.METHODSWe analyzed data from 524 families with PALB2 PVs from 21 countries. Complex segregation analysis was used to estimate relative risks (RRs; relative to country-specific population incidences) and absolute risks of cancers. The models allowed for residual familial aggregation of breast and ovarian cancer and were adjusted for the family-specific ascertainment schemes.RESULTSWe found associations between PALB2 PVs and risk of female breast cancer (RR, 7.18; 95% CI, 5.82 to 8.85; P = 6.5 × 10−76), ovarian cancer (RR, 2.91; 95% CI, 1.40 to 6.04; P = 4.1 × 10−3), pancreatic cancer (RR, 2.37; 95% CI, 1.24 to 4.50; P = 8.7 × 10−3), and male breast cancer (RR, 7.34; 95% CI, 1.28 to 42.18; P = 2.6 × 10−2). There was no evidence for increased risks of prostate or colorectal cancer. The breast cancer RRs declined with age ( P for trend = 2.0 × 10−3). After adjusting for family ascertainment, breast cancer risk estimates on the basis of multiple case families were similar to the estimates from families ascertained through population-based studies ( P for difference = .41). On the basis of the combined data, the estimated risks to age 80 years were 53% (95% CI, 44% to 63%) for female breast cancer, 5% (95% CI, 2% to 10%) for ovarian cancer, 2%-3% (95% CI females, 1% to 4%; 95% CI males, 2% to 5%) for pancreatic cancer, and 1% (95% CI, 0.2% to 5%) for male breast cancer.CONCLUSIONThese results confirm PALB2 as a major breast cancer susceptibility gene and establish substantial associations between germline PALB2 PVs and ovarian, pancreatic, and male breast cancers. These findings will facilitate incorporation of PALB2 into risk prediction models and optimize the clinical cancer risk management of PALB2 PV carriers.
Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis
Veer, Rozanne C. de , Thorburn, Douglas , Janssen, Harry L.A. , Lindor, Keith D. , Parés, Albert , Floreani, Annarosa , Mayo, Marlyn J. , Nevens, Frederik , Ponsioen, Cyriel Y. , Buuren, Henk R. van , van der Meer, Adriaan J , Harms, Maren H. , Lammers, Willem J. , Corpechot, Christophe , Trivedi, Palak Jitendrakumar , Hirschfield, Gideon M. , Invernizzi, Pietro , Battezzati, Pier Maria , Mason, Andrew L. , Kowdley, Kris V. , Hansen, Bettina E.

Mayo Clinic

Gut | December 16, 2019 | Volume: 69 | Issue: 8 | Pages: 1502-1509

10.1136/gutjnl-2019-319057 | PMID 31843787 Get It

Objective The clinical benefit of ursodeoxycholic acid (UDCA) in primary biliary cholangitis (PBC) has never been reported in absolute measures. The aim of this study was to assess the number needed to treat (NNT) with UDCA to prevent liver transplantation (LT) or death among patients with PBC. Methods The NNT was calculated based on the untreated LT-free survival and HR of UDCA with respect to LT or death as derived from inverse probability of treatment weighting-adjusted Cox proportional hazard analyses within the Global PBC Study Group database. Results We included 3902 patients with a median follow-up of 7.8 (4.1–12.1) years. The overall HR of UDCA was 0.46 (95% CI 0.40 to 0.52) and the 5-year LT-free survival without UDCA was 81% (95% CI 79 to 82). The NNT to prevent one LT or death within 5 years (NNT5y) was 11 (95% CI 9 to 13). Although the HR of UDCA was similar for patients with and without cirrhosis (0.33 vs 0.31), the NNT5y was 4 (95% CI 3 to 5) and 20 (95% CI 14 to 34), respectively. Among patients with low alkaline phosphatase (ALP) (≤2× the upper limit of normal (ULN)), intermediate ALP (2–4× ULN) and high ALP (>4× ULN), the NNT5y to prevent one LT or death was 26 (95% CI 15 to 70), 11 (95% CI 8 to 17) and 5 (95% CI 4 to 8), respectively. Conclusion The absolute clinical efficacy of UDCA with respect to LT or death varied with baseline prognostic characteristics, but was high throughout. These findings strongly emphasise the incentive to promptly initiate UDCA treatment in all patients with PBC and may improve patient compliance.
Senescence marker activin A is increased in human diabetic kidney disease: association with kidney function and potential implications for therapy
Bian, Xiaohui , Griffin, Tomás P. , Zhu, Xiangyang , Islam, Md Nahidul , Conley, Sabena M., Eirin, Alfonso , O’Shea, Paula , McCoy, Rozalina G. , Mehta, Ramila A. , Woollard, John R. , Kirkland, James L. , Textor, Stephen C., Griffin, Matthew D. , Lerman, Lilach O. , Palmer, Allyson K. , McCoy, Rozalina Grubina , Woollard, John R , Griffin, Matthew D , Lerman, Lilach O , Hickson, LaTonya J , Eirin, Alfonso , O'Shea, Paula M , Tang, Hui Jun , Herrmann, Sandra M. , Rule, Andrew D. , Tchkonia, Tamar , Hickson, LaTonya J.

Mayo Clinic

BMJ Open Diabetes Research & Care | December 16, 2019 | Volume: 7 | Issue: 1 | Pages: e000720

10.1136/bmjdrc-2019-000720 | PMID 31908790 Get It

Objective Activin A, an inflammatory mediator implicated in cellular senescence-induced adipose tissue dysfunction and profibrotic kidney injury, may become a new target for the treatment of diabetic kidney disease (DKD) and chronic kidney diseases. We tested the hypothesis that human DKD-related injury leads to upregulation of activin A in blood and urine and in a human kidney cell model. We further hypothesized that circulating activin A parallels kidney injury markers in DKD. Research design and methods In two adult diabetes cohorts and controls (Minnesota, USA; Galway, Ireland), the relationships between plasma (or urine) activin A, estimated glomerular filtration rate (eGFR) and DKD injury biomarkers were tested with logistic regression and correlation coefficients. Activin A, inflammatory, epithelial-mesenchymal-transition (EMT) and senescence markers were assayed in human kidney (HK-2) cells incubated in high glucose plus transforming growth factor-β1 or albumin. Results Plasma activin A levels were elevated in diabetes (n=206) compared with controls (n=76; 418.1 vs 259.3 pg/mL; p<0.001) and correlated inversely with eGFR (r s =−0.61; p<0.001; diabetes). After eGFR adjustment, only albuminuria (OR 1.56, 95% CI 1.16 to 2.09) and tumor necrosis factor receptor-1 (OR 6.40, 95% CI 1.08 to 38.00) associated with the highest activin tertile. Albuminuria also related to urinary activin (r s =0.65; p<0.001). Following in vitro HK-2 injury, activin, inflammatory, EMT genes and supernatant activin levels were increased. Conclusions Circulating activin A is increased in human DKD and correlates with reduced kidney function and kidney injury markers. DKD-injured human renal tubule cells develop a profibrotic and inflammatory phenotype with activin A upregulation. These findings underscore the role of inflammation and provide a basis for further exploration of activin A as a diagnostic marker and therapeutic target in DKD.